Pharmacogenetics of childhood acute lymphoblastic leukemia. (July 2014)

• Record Type: Journal Article
• Authors: Lopez-Lopez, Elixabet; Gutierrez-Camino, Angela; Bilbao-Aldaiturriaga, Nerea; Pombar-Gomez, Maria; Martin-Guerrero, Idoia; Garcia-Orad, Africa
• Is Part Of: Pharmacogenomics. Volume 15:Number 10(2014)
• Page Start: 1383
• Page End: 1398
• Publication Date: 2014-07
• Subjects: acute lymphoblastic leukemia -- childhood -- outcome -- pharmacogenetics -- toxicity -- treatment; Pharmacogenomics -- Periodicals; 615.1
• DOI: 10.2217/pgs.14.106
• Languages: English
• ISSNs: 1462-2416

Abstract

Acute lymphoblastic leukemia (ALL) is the major pediatric cancer in developed countries. Although treatment outcome has improved owing to advances in chemotherapy, there is still a group of patients for which therapy fails while some patients experience severe toxicity. In the last few years, several pharmacogenetic studies have been performed to search for markers of outcome and toxicity in pediatric ALL. However, to date, TPMT is the only pharmacogenetic marker in ALL with clinical guidelines for drug dosing. In this article, we will provide an overview of the most important findings carried out in pharmacogenetics for pediatric ALL, such as the interest drawn by methotrexate transporters in the context of methotrexate treatment. Even if most of the studies are centered on coding genes, we will also point to new approaches focusing on noncoding regions and epigenetic variation that could be interesting for consideration in the near future.